{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:51:28Z","timestamp":1791409888851,"version":"4.3.3"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019042","name":"Jiangsu Ocean University","doi-asserted-by":"publisher","award":["JOUMIRF008"],"award-info":[{"award-number":["JOUMIRF008"]}],"id":[{"id":"10.13039\/501100019042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018571","name":"Specific Research Project of Guangxi for Research Bases and Talents","doi-asserted-by":"publisher","award":["AD23026100"],"award-info":[{"award-number":["AD23026100"]}],"id":[{"id":"10.13039\/501100018571","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110390","type":"journal-article","created":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T12:05:19Z","timestamp":1786881919000},"page":"110390","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design and synthesis of long-acting prodrugs of SEP-363856 with sustained antipsychotic-like activity"],"prefix":"10.1016","volume":"181","author":[{"given":"Wenjing","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110390_bb0005","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","article-title":"Schizophrenia\u2014an overview","volume":"77","author":"McCutcheon","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.bioorg.2026.110390_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2023.11.015","article-title":"The schizophrenia syndrome, circa 2024: what we know and how that informs its nature","volume":"264","author":"Tandon","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bioorg.2026.110390_bb0015","article-title":"Pregnancy, delivery and neonatal complications in women with schizophrenia: a national population-based cohort study","volume":"10","author":"Fabre","year":"2021","journal-title":"Lancet Reg. Health Eur."},{"key":"10.1016\/j.bioorg.2026.110390_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104894","article-title":"Schizophrenia: the new etiological synthesis","volume":"142","author":"Rantala","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.bioorg.2026.110390_bb0025","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-025-00667-6","article-title":"Schizophrenia","volume":"11","author":"Leucht","year":"2025","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bioorg.2026.110390_bb0030","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1186\/s12888-021-03634-z","article-title":"Predicting time to relapse in patients with schizophrenia according to patients' relapse history: a historical cohort study using real-world data in Sweden","volume":"21","author":"J\u00f8rgensen","year":"2021","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.bioorg.2026.110390_bb0035","doi-asserted-by":"crossref","first-page":"39683","DOI":"10.4088\/JCP.SU21024IP1","article-title":"Emerging treatments in schizophrenia","volume":"83","author":"Correll","year":"2022","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bioorg.2026.110390_bb0040","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1056\/NEJMra1808803","article-title":"Schizophrenia","volume":"381","author":"Marder","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.110390_bb0045","article-title":"Editorial: reviews in psychiatry 2023: schizophrenia","volume":"15","author":"Tusconi","year":"2024","journal-title":"Front. Psychol."},{"key":"10.1016\/j.bioorg.2026.110390_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2025.116856","article-title":"Cognition in schizophrenia across phases of illness: a systematic review and meta-analysis","volume":"355","author":"Howie","year":"2026","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.bioorg.2026.110390_bb0055","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/wps.20972","article-title":"Oral and long-acting injectable antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomised trials including 22,645 participants","volume":"21","author":"Ostuzzi","year":"2022","journal-title":"World Psychiatry"},{"key":"10.1016\/j.bioorg.2026.110390_bb0060","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.euroneuro.2023.04.015","article-title":"Comparing the pharmacology and pharmacokinetics of antipsychotics: choosing an antipsychotic and dosing a long-acting injectable","volume":"73","author":"Meyer","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.bioorg.2026.110390_bb0065","article-title":"Effect of long-acting injectable antipsychotics on hospitalizations and global functioning in schizophrenia: a naturalistic mirror-image study","volume":"12","author":"Correll","year":"2022","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.bioorg.2026.110390_bb0070","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","article-title":"Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"9","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.bioorg.2026.110390_bb0075","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41537-023-00356-x","article-title":"Influencing factors of medication adherence in schizophrenic patients: a meta-analysis","volume":"9","author":"Guo","year":"2023","journal-title":"Schizophrenia (Heidelberg)"},{"key":"10.1016\/j.bioorg.2026.110390_bb0080","article-title":"Advances in implementation strategies for treatment adherence in schizophrenia: a narrative review","volume":"17","author":"Shen","year":"2026","journal-title":"Front. Psychol."},{"key":"10.1016\/j.bioorg.2026.110390_bb0085","doi-asserted-by":"crossref","DOI":"10.1177\/20451253251360400","article-title":"Effect of long-acting injectable antipsychotics on treatment adherence and healthcare utilization in Chinese patients with schizophrenia: a mirror-image study","volume":"15","author":"Zhang","year":"2025","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.bioorg.2026.110390_bb0090","doi-asserted-by":"crossref","DOI":"10.1038\/s41537-021-00190-z","article-title":"Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study","volume":"7","author":"Correll","year":"2021","journal-title":"NPJ Schizophr."},{"key":"10.1016\/j.bioorg.2026.110390_bb0095","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1056\/NEJMoa1911772","article-title":"A non-D2-receptor-binding drug for the treatment of schizophrenia","volume":"382","author":"Koblan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.110390_bb0100","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1021\/acsmedchemlett.1c00527","article-title":"Ulotaront: a TAAR1 agonist for the treatment of schizophrenia","volume":"13","author":"Heffernan","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110390_bb0105","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/13543784.2023.2206559","article-title":"Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials","volume":"32","author":"Le","year":"2023","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bioorg.2026.110390_bb0110","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/psp4.12692","article-title":"Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia","volume":"10","author":"Galluppi","year":"2021","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110390_bb0115","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyaf059","article-title":"Trajectory of efficacy and safety across ulotaront dose levels in schizophrenia: a systematic review and dose-response meta-analysis","volume":"28","author":"Hsu","year":"2025","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.bioorg.2026.110390_bb0120","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s11095-022-03267-1","article-title":"In vitro ADME and preclinical pharmacokinetics of ulotaront, a TAAR1\/5-HT1A receptor agonist for the treatment of schizophrenia","volume":"39","author":"Xiao","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bioorg.2026.110390_bb0125","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s40262-023-01317-4","article-title":"A phase I, open-label, fixed sequence study to investigate the effect of cytochrome P450 2D6 inhibition on the pharmacokinetics of ulotaront in healthy subjects","volume":"62","author":"Tsukada","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bioorg.2026.110390_bb0130","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00406-023-01580-3","article-title":"Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia","volume":"273","author":"Achtyes","year":"2023","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.bioorg.2026.110390_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/ph18030297","article-title":"Prodrug approach as a strategy to enhance drug permeability","volume":"18","author":"de Souza","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2026.110390_bb0140","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1039\/D2CS00957A","article-title":"Prodrugs as empowering tools in drug discovery and development: recent strategic applications of drug delivery solutions to mitigate challenges associated with lead compounds and drug candidates","volume":"53","author":"Subbaiah","year":"2024","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bioorg.2026.110390_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114860","article-title":"Prodrug approaches for the development of a long-acting drug delivery systems","volume":"198","author":"Chien","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioorg.2026.110390_bb0150","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1039\/D2SC01003H","article-title":"Stimulus-responsive self-assembled prodrugs in cancer therapy","volume":"13","author":"Dong","year":"2022","journal-title":"Chem. Sci."},{"key":"10.1016\/j.bioorg.2026.110390_bb0155","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41573-024-00914-7","article-title":"The landscape of small-molecule prodrugs","volume":"23","author":"Fralish","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110390_bb0160","first-page":"35","article-title":"Discontinuing a long-acting injectable antipsychotic: what to consider","volume":"22","author":"Ehret","year":"2023","journal-title":"Curr. Psychiatr. Ther."},{"key":"10.1016\/j.bioorg.2026.110390_bb0165","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/pharmaceutics16010028","article-title":"Long-acting injectable antipsychotics\u2014a review on formulation and in vitro dissolution","volume":"16","author":"Markowicz-Piasecka","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2026.110390_bb0170","series-title":"Long-Acting Injectable Medications in Mental Health","first-page":"15","article-title":"Haloperidol decanoate: First-generation antipsychotic long-acting injectable","author":"Ehret","year":"2025"},{"key":"10.1016\/j.bioorg.2026.110390_bb0175","series-title":"Long-Acting Injectable Medications in Mental Health","first-page":"45","article-title":"Paliperidone palmitate (Invega Sustenna\u00ae): Second-generation antipsychotic long-acting injectable","author":"Ehret","year":"2025"},{"key":"10.1016\/j.bioorg.2026.110390_bb0180","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2147\/NDT.S499367","article-title":"Aripiprazole lauroxil: development and evidence-based review of a long-acting injectable atypical antipsychotic for the treatment of schizophrenia","volume":"21","author":"Citrome","year":"2025","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.bioorg.2026.110390_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116646","article-title":"Design, synthesis and evaluation of carbamate-bridged amino acid prodrugs of cycloicaritin with improved antitumor activity, aqueous solubility and phase II metabolic stability","volume":"276","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110390_bb0190","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1039\/D4MD00788C","article-title":"Prodrugs and their activation mechanisms for brain drug delivery","volume":"16","author":"Lillethorup","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110390_bb0195","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1021\/acsmedchemlett.2c00492","article-title":"Sulfonamide prodrugs with a two-stage release mechanism for the efficient delivery of the TLR4 antagonist TAK-242","volume":"14","author":"Kostyo","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110390_bb0200","first-page":"928","article-title":"Improvement of resolution process for schizophrenia candidate drug ulotaront hydrochloride","volume":"55","author":"Xue","year":"2024","journal-title":"Chin. J. Pharm."},{"key":"10.1016\/j.bioorg.2026.110390_bb0205","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/wps.20693","article-title":"Dopamine and glutamate in schizophrenia: biology, symptoms and treatment","volume":"19","author":"McCutcheon","year":"2020","journal-title":"World Psychiatry"},{"key":"10.1016\/j.bioorg.2026.110390_bb0210","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2147\/NDT.S455279","article-title":"New therapeutic targets and drugs for schizophrenia beyond dopamine D2 receptor antagonists","volume":"20","author":"Peng","year":"2024","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.bioorg.2026.110390_bb0215","doi-asserted-by":"crossref","first-page":"10668","DOI":"10.3390\/ijms251910668","article-title":"Advances in the treatment of cognitive impairment in schizophrenia: targeting NMDA receptor pathways","volume":"25","author":"Zhang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110390_bb0220","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.3390\/molecules27082550","article-title":"Effect of co-treatment of olanzapine with SEP-363856 in mice models of schizophrenia","volume":"27","author":"Liang","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.110390_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114649","article-title":"Benzylaminofentanyl derivatives: discovery of bifunctional \u03bc opioid and \u03c31 receptor ligands as novel analgesics with reduced adverse effects","volume":"241","author":"Zhuang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110390_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.pscia.2025.100099","article-title":"Discovery of a long-acting nanocrystal formulation of INND-2201, a new co-drug of pregabalin and palmitoylethanolamide with synergistic analgesic effects","volume":"3","author":"Han","year":"2025","journal-title":"Pharm. Sci. Adv."},{"key":"10.1016\/j.bioorg.2026.110390_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177919","article-title":"Discovery of two new co-drugs of celecoxib and gabapentinoids for treating chemotherapy-induced peripheral neuropathy","volume":"1003","author":"Yin","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110390_bb0240","doi-asserted-by":"crossref","first-page":"697","DOI":"10.5607\/en.2019.28.6.697","article-title":"Recapitulation of neuropsychiatric behavioral features in mice using acute low-dose MK-801 administration","volume":"28","author":"Mabunga","year":"2019","journal-title":"Exp. Neurobiol."},{"key":"10.1016\/j.bioorg.2026.110390_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2026.118616","article-title":"Discovery of 3-indolealkylamines as novel dual-target \u03c31R\/H3R ligands with potent analgesia","volume":"306","author":"Chen","year":"2026","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110390_bb0250","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.22225","article-title":"SEP-363856 exerts neuroprotection through the PI3K\/AKT\/GSK-3\u03b2 signaling pathway in a dual-hit neurodevelopmental model of schizophrenia-like mice","volume":"85","author":"Li","year":"2024","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bioorg.2026.110390_bb0255","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.1001869","article-title":"Behavioral features and disorganization of oscillatory activity in C57BL\/6J mice after acute low dose MK-801 administration","volume":"16","author":"Cui","year":"2022","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bioorg.2026.110390_bb0260","doi-asserted-by":"crossref","first-page":"16931","DOI":"10.1039\/D1RA02426D","article-title":"Synthesis and biological evaluation of a new class of multi-target heterocycle piperazine derivatives as potential antipsychotics","volume":"11","author":"Gao","year":"2021","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2026.110390_bb0265","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1298061","article-title":"Assessing NH300094, a novel dopamine and serotonin receptor modulator with cognitive enhancement property for treating schizophrenia","volume":"15","author":"Feng","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110390_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2026.119073","article-title":"Discovery of novel N-(alkylpiperidinyl) substituted benzamides targeting the glycine transporter 2 with anti-nociceptive effects in neuropathic pain","volume":"317","author":"Yao","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110390_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114437","article-title":"Simultaneous determination of ZL-01, a novel nucleotide prodrug, and its metabolites in rat plasma by LC-MS\/MS: application to pharmacokinetic study","volume":"208","author":"Chang","year":"2022","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826009260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826009260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:09:59Z","timestamp":1791407399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826009260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":55,"alternative-id":["S0045206826009260"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110390","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and synthesis of long-acting prodrugs of SEP-363856 with sustained antipsychotic-like activity","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110390","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110390"}}